logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
Purified Anti-human CD10 Antibody
HI10a
HI10a is an anti-human monoclonal antibody that targets the CD10 antigen. CD10 (also known as EPN, MME, CALLA or Neprilysin) is a 100 kD single-pass type II membrane protein that is expressed on the surface of cells such as NK cells and endothelial cells. CD10 has been closely linked to essential biological processes like amyloid-beta clearance, particularly amyloid-beta clearance by cellular catabolic process. Also, in some organisms, it is involved in the positive regulation of long-term synaptic potentiation and is a promoter of neurogenesis. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands like . CD10 is a fairly uncommon antibody target, with a little more than 9600 publications in the last decade. Even still, CD10 has been widely used in immunology research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography.
General packaging for catalog 10100000. Actual shipped packaging may vary.
General packaging for catalog 10100000. Actual shipped packaging may vary.
CatalogSize
Price
Quantity
10100000100 ug
Price
 
Physical properties

Molecular weightN/A
Solventwater
Antibody properties

Other namesCALLA; MME; Neprilysin
CloneHI10a
Hostmouse
Isotypemouse IgG1
Reactivityhuman
ApplicationFlow Cytometry (FACS); ELISA; IHC; Western Blot
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageRefrigerated (2-8 °C); Minimize light exposure
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on September 26, 2025